We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanolock Sensor Detects Cancer Driver Mutation

By LabMedica International staff writers
Posted on 24 Jul 2017
Researchers have developed an accurate and sensitive “nanolock-nanopore” method that successfully diagnosed a known cancer driver mutation with results at the level of single DNA molecules in tumor tissues of thyroid cancer patients. More...
The method can be adapted to detect a broad spectrum of both transversion and transition mutations, with applications from early diagnostics to individualized targeted therapy and monitoring.

Cancer driver mutations assist in the initiation and progression of cancers, many of which can be stopped in time if caught early enough. The current method for detecting driver mutations is real-time PCR, but it is not accurate enough to detect these genetic changes reliably. Researchers have developed methods to read the genetic sequence by moving it through a nanopore, but also this method is not accurate enough on its own.

Building on their previous work, Prof. Li-Qun Gu, of University of Missouri (Columbia, MO, USA), and colleagues sought a way to better pinpoint these mutations, and with single-molecule resolution. They developed and investigated their novel method using as a test case the known BRAF V600E mutation. The team has now found that mutant DNA carrying a nanolock undergoes a unique type of unzipping when it moves through the nanopore. Detecting this activity resulted in a highly accurate and sensitive nanopore fingerprint for the BRAF mutation in the thyroid cancer patients’ tumor tissue samples.

The researchers anticipate the approach, once integrated with a miniature high-throughput device, could enable PCR-free detection of various disease-causing mutations for diagnosis and prognosis.

The study, by Wang Y et al, was published July 5, 2017, in the journal ACS Sensors.

Related Links:
University of Missouri


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.